An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer
This is a phase 2, multicenter, single arm, open-lable study of ICP-192. The purpose of this study is to evaluate efficacy of ICP-192 in subjects with surgically unresectable or metastatic bladder urothelial cancer.
Bladder Urothelial Cancer
DRUG: ICP-192
ORR, Objective Response Rate, From the time of first dose until objective disease progression, an average of 6 months
DOR, Duration of response, From the time of first dose until objective disease progression, an average of 6 months|DCR, Disease Control Rate, From the time of first dose until objective disease progression, an average of 6 months|PFS, Progression Free Survival, From the time of first dose until objective disease progression, an average of 6 months|OS, Overall survival, From the time of first dose until objective disease progression, an average of 1 months
bladder urothelial cancer